Andrea Jewell, MD
Obstetrics & Gynecology · Kansas City, KSNPI 1598923641
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $586 of the $699 with a category attached, or 83.8%. 6 manufacturers reported payments, led by AbbVie at 29.7% of the total. 2025 is the largest year on record at $355, 2.9 times the $121 reported in 2019. That places this record below the midpoint for obstetrics & gynecology clinicians in KS, where the typical reported total is $738.
Across 22 payments — averaging $31.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$207
- AstraZeneca$169
- Merck$139
- Tesaro, Inc.$121
- GSK$45
- Genmab U.S., Inc.$17
Across 767 payments — averaging $4171.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genmab U.S., Inc.$984K
- Tesaro, Inc.$618K
- GSK$507K
- Seagen Inc.$321K
- Deciphera Pharmaceuticals Inc.$313K
- Clovis Oncology, Inc.$166K
- plus $291K from 8 others
What the payments were for
- Food & beverage$58684%
- Education$11316%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $207 |
| AstraZeneca | 4 | $169 |
| Merck | 6 | $139 |
| Tesaro, Inc. | 1 | $121 |
| GSK | 1 | $45 |
| Genmab U.S., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$121
How this compares
$699 in reported general payments places this provider in the 45th percentile of 302 obstetrics & gynecology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 14 | $13,775 |
| Megestrol Acetate | 30 | $851 |
| Tamoxifen Citrate | 11 | $435 |
| Gabapentin | 34 | $217 |
| Dexamethasone | 21 | $204 |
| Nystatin | 17 | $204 |
| Letrozole | 14 | $184 |
| Prochlorperazine Maleate | 15 | $149 |
| Metronidazole | 11 | $133 |
| Ondansetron Hcl | 23 | $88 |
| Methylprednisolone | 14 | $61 |
| Medroxyprogesterone Acetate | 13 | $30 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Kansas City
- Austin FindleyKansas City$18K
- Madhuri ReddyKansas City$13K
- Melanie MeisterKansas City$6K
- Erin CareyKansas City$6K
- Meredith GrayKansas City$6K
- Linden CollinsKansas City$4K
- Sherebanu GaslightwalaKansas City$3K
- Kristi Weaver RoweKansas City$3K
- Kimberly SwanOverland Park$123K
- Michael FenechPittsburg$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.